BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...deal will give it an earlier-stage, best-in-class product against the same target.Boehringer Ingelheim GmbH will acquire NBE-Therapeutics AG...
...including oncolytic viruses.TARGETSROR1 - Receptor tyrosine kinase-like orphan receptor 1 Paul Bonanos Boehringer Ingelheim GmbH Boehringer Ingelheim Venture Fund NBE-Therapeutics AG bee2021...
BioCentury | Dec 8, 2020
Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

...listed on ClinicalTrials.gov. In October, Swiss biotech NBE-Therapeutics AG...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...and is eligible for $353.3 million in milestones, plus tiered royalties.Also in October, Swiss biotech NBE-Therapeutics AG...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...NBE enter exclusive multi-target ADC dealSwiss biotech NBE-Therapeutics AG...
BioCentury | Aug 13, 2020
Management Tracks

NHC’s Boutin to head patient advocacy at Novartis; plus changes at Moderna, PIC, Atea, Terns, NBE and Omega

...CFO of Applied Therapeutics Inc. (NASDAQ:APLT). Additionally, CMO Erin Quirk will also serve as president.Antibody-drug conjugate developer NBE-Therapeutics AG...
...has raised $85 million to develop therapies targeting chromatin structures. Robin Sawka Atea Pharmaceuticals Inc. Moderna Inc. Terns Pharmaceuticals Inc. NBE-Therapeutics AG Novartis...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...over $2 billion in a June IPO (see “Royalty’s $1.7B IPO” ). Antibody-drug conjugate developer NBE-Therapeutics AG...
...Targets GM-CSF (CSF2) - Granulocyte macrophage colony-stimulating factor Robin Sawka, BioCentury Staff CureVac AG Legend Biotech Corp. Royalty Pharma plc NBE-Therapeutics AG Black...
BioCentury | Apr 11, 2019
Company News

WuXi Biologics to manufacture NBE’s ADC for clinical trials

...clinical trials worldwide. NBE-Therapeutics AG (Basel, Switzerland) plans to begin trials of the ADC in mid-2020. NBE-Therapeutics...
...triple-negative breast cancer (TNBC), lung cancer, chronic lymphocytic leukemia and mantle cell lymphoma. Hongjiang Li, Staff Writer NBE-002 NBE-Therapeutics AG WuXi...
BioCentury | Nov 4, 2016
Financial News

NBE raises CHF20M in series B

...the time that PPF would invest CHF10 million ($10.1 million) in NBE's next financing round. Becky Simon NBE-Therapeutics AG...
BioCentury | Nov 4, 2016
Financial News

NBE-Therapeutics completes venture financing

...the company's existing private investors and one new undisclosed investor participated. NBE-Therapeutics AG , Basel, Switzerland Alex Himes NBE-Therapeutics AG...
BioCentury | Oct 24, 2016
Company News

NBE-Therapeutics, Sotio deal

...royalties, and will be reimbursed for R&D expenses. The companies declined to disclose financial terms. NBE-Therapeutics AG...
Items per page:
1 - 10 of 11
BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...deal will give it an earlier-stage, best-in-class product against the same target.Boehringer Ingelheim GmbH will acquire NBE-Therapeutics AG...
...including oncolytic viruses.TARGETSROR1 - Receptor tyrosine kinase-like orphan receptor 1 Paul Bonanos Boehringer Ingelheim GmbH Boehringer Ingelheim Venture Fund NBE-Therapeutics AG bee2021...
BioCentury | Dec 8, 2020
Product Development

ADC and ROR1 momentum grows with ASH data behind Merck, VelosBio deal

...listed on ClinicalTrials.gov. In October, Swiss biotech NBE-Therapeutics AG...
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...and is eligible for $353.3 million in milestones, plus tiered royalties.Also in October, Swiss biotech NBE-Therapeutics AG...
BioCentury | Sep 9, 2020
Product Development

Sept. 8 Quick Takes: Phase III wins for Albireo, Merck and Spero; plus Corbus, Blueprint, AnHeart, Grifols-Alkahest, and Exelixis-NBE

...NBE enter exclusive multi-target ADC dealSwiss biotech NBE-Therapeutics AG...
BioCentury | Aug 13, 2020
Management Tracks

NHC’s Boutin to head patient advocacy at Novartis; plus changes at Moderna, PIC, Atea, Terns, NBE and Omega

...CFO of Applied Therapeutics Inc. (NASDAQ:APLT). Additionally, CMO Erin Quirk will also serve as president.Antibody-drug conjugate developer NBE-Therapeutics AG...
...has raised $85 million to develop therapies targeting chromatin structures. Robin Sawka Atea Pharmaceuticals Inc. Moderna Inc. Terns Pharmaceuticals Inc. NBE-Therapeutics AG Novartis...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...over $2 billion in a June IPO (see “Royalty’s $1.7B IPO” ). Antibody-drug conjugate developer NBE-Therapeutics AG...
...Targets GM-CSF (CSF2) - Granulocyte macrophage colony-stimulating factor Robin Sawka, BioCentury Staff CureVac AG Legend Biotech Corp. Royalty Pharma plc NBE-Therapeutics AG Black...
BioCentury | Apr 11, 2019
Company News

WuXi Biologics to manufacture NBE’s ADC for clinical trials

...clinical trials worldwide. NBE-Therapeutics AG (Basel, Switzerland) plans to begin trials of the ADC in mid-2020. NBE-Therapeutics...
...triple-negative breast cancer (TNBC), lung cancer, chronic lymphocytic leukemia and mantle cell lymphoma. Hongjiang Li, Staff Writer NBE-002 NBE-Therapeutics AG WuXi...
BioCentury | Nov 4, 2016
Financial News

NBE raises CHF20M in series B

...the time that PPF would invest CHF10 million ($10.1 million) in NBE's next financing round. Becky Simon NBE-Therapeutics AG...
BioCentury | Nov 4, 2016
Financial News

NBE-Therapeutics completes venture financing

...the company's existing private investors and one new undisclosed investor participated. NBE-Therapeutics AG , Basel, Switzerland Alex Himes NBE-Therapeutics AG...
BioCentury | Oct 24, 2016
Company News

NBE-Therapeutics, Sotio deal

...royalties, and will be reimbursed for R&D expenses. The companies declined to disclose financial terms. NBE-Therapeutics AG...
Items per page:
1 - 10 of 11